← FDA DRUG APPROVALS

FDA ANDA · ANDA090695

LOXAPINE

Sponsor: LANNETT CO INC

APPLICATION
ANDA090695
TYPE
ANDA
ORIGINAL APPROVAL
2011-09-26
LATEST ACTION
2025-01-22
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

LOXAPINE SUCCINATEPrescription
LOXAPINE SUCCINATE EQ 50MG BASE · CAPSULE · ORAL
LOXAPINE SUCCINATEPrescription
LOXAPINE SUCCINATE EQ 10MG BASE · CAPSULE · ORAL
LOXAPINE SUCCINATEPrescription
LOXAPINE SUCCINATE EQ 25MG BASE · CAPSULE · ORAL
LOXAPINE SUCCINATEPrescription
LOXAPINE SUCCINATE EQ 5MG BASE · CAPSULE · ORAL

Approval history

2025-01-22Labeling · Supplement 19 · standardAP
2017-02-23Labeling · Supplement 5 · standardAP
2011-09-26OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →